Nkarta (NASDAQ:NKTX) Given New $36.00 Price Target at HC Wainwright

Nkarta (NASDAQ:NKTX – Get Rating) had its price objective increased by equities researchers at HC Wainwright from $25.00 to $36.00 in a research report issued on Monday, The Fly reports. HC Wainwright’s price objective points to a potential upside of 123.88% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Nkarta in a research report on Tuesday, March 29th. Zacks Investment Research upgraded shares of Nkarta from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Tuesday, April 5th. William Blair began coverage on shares of Nkarta in a research report on Thursday, January 6th. They set an “outperform” rating and a $35.00 price objective on the stock. Finally, Raymond James began coverage on shares of Nkarta in a research report on Friday, March 11th. They issued an “outperform” rating and a $17.00 target price on the stock. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Nkarta has an average rating of “Buy” and a consensus target price of $50.56.

Shares of Nkarta stock traded up $8.31 on Monday, hitting $16.08. 1,693,384 shares of the company traded hands, compared to its average volume of 211,290. The firm’s 50-day simple moving average is $10.13 and its 200 day simple moving average is $13.14. The company has a market cap of $530.66 million, a P/E ratio of -6.18 and a beta of 1.27. Nkarta has a 12-month low of $7.55 and a 12-month high of $40.64.

Nkarta (NASDAQ:NKTX – Get Rating) last posted its quarterly earnings data on Thursday, March 17th. The company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.06. Research analysts forecast that Nkarta will post -3.07 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in Nkarta by 0.6% in the 3rd quarter. BlackRock Inc. now owns 1,361,219 shares of the company’s stock worth $37,854,000 after purchasing an additional 8,393 shares during the period. Deep Track Capital LP purchased a new position in shares of Nkarta in the fourth quarter valued at about $19,409,000. Wasatch Advisors Inc. increased its position in shares of Nkarta by 17.6% in the fourth quarter. Wasatch Advisors Inc. now owns 631,602 shares of the company’s stock valued at $9,695,000 after acquiring an additional 94,678 shares during the period. Rock Springs Capital Management LP increased its position in shares of Nkarta by 1.0% in the third quarter. Rock Springs Capital Management LP now owns 503,148 shares of the company’s stock valued at $13,993,000 after acquiring an additional 5,200 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Nkarta by 851.7% in the third quarter. Goldman Sachs Group Inc. now owns 233,688 shares of the company’s stock valued at $6,499,000 after acquiring an additional 209,133 shares during the period. Institutional investors own 71.46% of the company’s stock.

Nkarta Company Profile (Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Featured Articles